anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Source Note

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 110,355
Current window 73,411-73,440
Pages 3,679
Rows per page 30
Component: Source Noteclear collectionreset all
18 30 60

Component

73,411-73,440 of 110,355

filter-aware
15
The table uses a structured approach to categorize clinical trials into Foundational, Alternative Dosing, and Registrational enabling.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
17
The slide presents clinical trial safety data (ARTISTRY-1) comparing monotherapy and combination therapy cohorts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
18
The slide uses a human body diagram to map clinical responses (CR, PR, uPR) by tumor type and treatment regimen.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
19
Includes a swimmer plot (onco-plot) and a summary table of best overall response (BOR) metrics.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
20
The slide uses a timeline to track treatment milestones and CT scans to show tumor reduction from baseline to complete response.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
21
Includes a swimmer plot (left) and a summary table (right) with clinical trial metrics.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Loop · Before After1 hit
22
The slide outlines a clinical trial protocol with three distinct cohorts and specific dosing schedules.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
23
Clinical trial design diagram showing randomization, arms, dosing schedules, and endpoints.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
24
The slide uses a hub-and-spoke diagram for the mechanistic combinations.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
27
The slide uses a process diagram to show the IL-18 signaling cascade (IL-18 -> MYD88 -> IRAK -> NFkB -> IFNy) and a numbered list to detail its immunomodulatory functions.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
28
Uses a combination of a scatter plot and biological mechanism diagrams to illustrate the inhibitory effect of IL-18BP.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
29
Uses a before-after-bridge framework to illustrate the mechanism of action for the therapeutic candidate.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
30
Data shows that while WT IL-18 is inhibited by IL-18BP, the variants are resistant to this inhibition.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
31
The slide uses a diagram to illustrate the activation of immune cells (NKT, NK, CD4, CD8) by IL-12, leading to IFN-gamma production and subsequent downstream effects.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
33
Includes a bar chart showing dose-dependent PD response in a mouse model and a schematic of the split IL-12 mechanism.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
35
Includes a footnote regarding patient enrollment for clinical milestones.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Financials1 hit
36
Uses a numbered list format to highlight key company facts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Financials1 hit
05
Includes a blue box highlight around the Q3'23 column.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations 1 hit
10
The chart tracks TRx (Total Prescriptions) over 101 weeks.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
11
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
14
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
15
The slide illustrates the escalation of doses for both SAD and MAD study arms.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
16
SAD: Single Ascending Dose; MAD: Multiple Ascending Dose; AE: Adverse Event; SAE: Serious Adverse Event.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
17
Includes box plots for AUC and Cmax across dose levels (1, 3, 8, 15, 25, 50 mg).Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
18
The diagram illustrates a 4-way cross-over design with 4 patients, each receiving a different sequence of placebo and three dose levels (1mg, 3mg, 8mg).Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
20
The table displays n (%) for adverse events related to the study drug.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
21
Data represents NT1 patients; N=4 per dose; P-values indicate statistical significance vs placebo.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
03
The slide includes a footnote explaining the F/X adjusted metric.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · What Is1 hit
04
The slide uses a bar chart for time-series growth and a pie chart for segment composition.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · What Is1 hit
07
Includes a footnote explaining the impact of Rivian Automotive investment valuation gains on net income.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · What Is1 hit